Valeant Pharmaceuticals Inc won't pay whatever it takes to acquire rival Allergan Inc , and it will not turn its bid into an all-cash deal, Valeant Chief Executive Michael Pearson said on Tuesday in New York. Valeant and activist investor Bill Ackman made an unsolicited $47 billion bid to purchase Botox maker Allergan as it seeks to become one of the world's five biggest drug companies.
Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN traded higher by 15.64% or $22.2125/share to $164.21. In the past year, the shares have traded as low as $81.33 and as high as $142.00. On average, 3082310 shares of AGN exchange hands on a given day and today's volume is recorded at 28770960.
Source